论文部分内容阅读
目的探讨左炔诺孕酮宫内缓释系统治疗子宫内膜癌癌前病变患者的临床效果。方法选取2013年1月-2014年1月该院收治的子宫内膜癌癌前病变患者31例,按照自愿原则分为观察组15例及对照组16例,观察组应用左炔诺孕酮宫内缓释系统治疗,对照组应用甲羟孕酮治疗,对比两组患者治疗效果。结果治疗前两组患者PBAC评分差异无统计学意义(t=1.029,P>0.05),治疗后两组患者均有一定改善,与治疗前比较差异有统计学意义(F=9.128、8.234,均P<0.05),观察组患者显著低于对照组,差异有统计学意义(t=12.935、15.025、19.834,均P<0.05);治疗前两组患者子宫内膜厚度差异无统计学意义(t=1.326,P>0.05),治疗后两组患者均有一定程度变薄,与治疗前比较差异有统计学意义(F=8.996、8.329,均P<0.05),观察组患者变薄程度显著高于对照组,差异有统计学意义(t=11.915,12.316、11.846,均P<0.05);治疗前两组患者血红蛋白水平差异无统计学意义(t=1.943,P>0.05),治疗后两组患者均有一定程度上升,与治疗前比较差异有统计学意义(F=9.006、8.193,均P<0.05),观察组升高程度高于对照组,差异有统计学意义(t=10.864、11.902、13.458,均P<0.05);同时观察组子宫内膜缓解率显著高于对照组,差异有统计学意义(χ~2=5.105、5.391、5.125,均P<0.05)。结论左炔诺孕酮宫内缓释系统治疗子宫内膜癌癌前病变患者的效果理想,对有生育需求的患者以及不耐受手术患者有重要应用价值。
Objective To investigate the clinical efficacy of levonorgestrel-releasing intrauterine system in the treatment of precancerous lesions of endometrial cancer. Methods From January 2013 to January 2014, 31 patients with precancerous lesions of endometrial cancer admitted to our hospital from January 2013 to January 2014 were divided into observation group (n = 15) and control group (n = 16) according to the voluntary principle. The observation group was treated with levonorgestrel Within the system of sustained release, the control group, medroxyprogesterone acetate treatment, the treatment effect of two groups were compared. Results There was no significant difference in PBAC score between the two groups before treatment (t = 1.029, P> 0.05). After treatment, both groups had some improvement, which were significantly different from those before treatment (F = 9.128, 8.234, (T = 12.935,15.025, 19.834, all P <0.05). There was no significant difference in the endometrial thickness between the two groups before treatment (t = 1.326, P> 0.05). After treatment, the patients in both groups had a certain degree of thinning, which was significantly different from that before treatment (F = 8.996 and 8.329, all P <0.05) (T = 11.915, 12.316, 11.846, all P <0.05). There was no significant difference in hemoglobin levels between the two groups before treatment (t = 1.943, P> 0.05). After treatment, the two groups The patients had a certain degree of increase, with statistical significance (F = 9.006, 8.193, all P <0.05), the level of the observation group was higher than that of the control group, the difference was statistically significant (t = 10.864,11.902 , 13.458, all P <0.05); while the endometrial remission rate of the observation group was significantly higher than that of the control group (χ ~ 2 = 5.105,5.391,5.125, All P <0.05). Conclusion Levonorgestrel-releasing intrauterine system is effective in the treatment of patients with precancerous lesions of endometrial cancer. It is of great value to patients with reproductive needs and patients with intolerance.